Duchenne muscular dystrophy is among the most severe forms of inherited muscular dystrophy. In this article, we look at seven clinical stage biotech companies that are fostering research and development (R&D) in Duchenne muscular dystrophy care. For Duchenne muscular dystrophy disease, the American company has developed WVE-N531, which is an antisense oligonucleotide that can skip exons. Dyne also has exon 53, 45, 44, and 55 skippers being tested in early preclinical studies for Duchenne muscular dystrophy. In the news: treating Duchenne in 2026Quite a bit has been going on in the Duchenne muscular dystrophy space of late.